Core Viewpoint - Karyopharm Therapeutics (KPTI) is expected to report a year-over-year decline in earnings and revenues for the quarter ended June 2025, with the consensus outlook indicating a loss of $3.80 per share and revenues of $40.08 million, reflecting a 26.7% and 6.3% decrease respectively [1][3]. Earnings Expectations - The upcoming earnings report could lead to a stock price increase if the actual results exceed expectations, while a miss could result in a decline [2]. - The consensus EPS estimate has been revised 2.21% lower in the last 30 days, indicating a reassessment by analysts [4]. Earnings Surprise Prediction - The Zacks Earnings ESP model suggests that Karyopharm has a positive Earnings ESP of +0.92%, indicating a likelihood of beating the consensus EPS estimate [12]. - The stock currently holds a Zacks Rank of 3, which supports the potential for an earnings beat [12]. Historical Performance - Karyopharm has a history of exceeding consensus EPS estimates, having beaten expectations in the last four quarters [14]. - In the last reported quarter, the company was expected to post a loss of $4.21 per share but actually reported a loss of -$2.77, resulting in a positive surprise of +34.20% [13]. Industry Context - In the Zacks Medical - Drugs industry, Ardelyx (ARDX) is expected to report a loss of $0.13 per share, indicating a significant year-over-year decline of 85.7%, with revenues projected at $84.64 million, up 15.6% from the previous year [18]. - Ardelyx's consensus EPS estimate has been revised 6.3% lower, resulting in a negative Earnings ESP of -6.18%, combined with a Zacks Rank of 4, making it difficult to predict an earnings beat [19].

Core Viewpoint - Lithia Motors reported quarterly earnings of $10.24 per share, exceeding the Zacks Consensus Estimate of $9.78 per share, and showing an increase from $7.87 per share a year ago, indicating a positive earnings surprise of +4.70% [1][2] Financial Performance - The company achieved revenues of $9.58 billion for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 0.52%, and up from $9.23 billion in the same quarter last year [2] - Over the last four quarters, Lithia Motors has exceeded consensus EPS estimates three times and topped revenue estimates twice [2] Stock Performance - Lithia Motors shares have declined approximately 14.1% since the beginning of the year, contrasting with the S&P 500's gain of 8.6% [3] - The current Zacks Rank for Lithia Motors is 3 (Hold), suggesting that the shares are expected to perform in line with the market in the near future [6] Future Outlook - The consensus EPS estimate for the upcoming quarter is $8.88 on revenues of $9.83 billion, while for the current fiscal year, the estimate is $35.14 on revenues of $38.55 billion [7] - The outlook for the automotive retail and wholesale industry, where Lithia Motors operates, is currently in the bottom 37% of Zacks industries, which may impact stock performance [8]

Core Viewpoint - Cincinnati Financial (CINF) reported quarterly earnings of $1.97 per share, exceeding the Zacks Consensus Estimate of $1.39 per share, and showing an increase from $1.29 per share a year ago, representing an earnings surprise of +41.73% [1][2] Financial Performance - The company posted revenues of $2.78 billion for the quarter ended June 2025, slightly missing the Zacks Consensus Estimate by 0.14%, compared to $2.41 billion in the same quarter last year [2] - Over the last four quarters, Cincinnati Financial has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Performance - Cincinnati Financial shares have increased by approximately 4% since the beginning of the year, while the S&P 500 has gained 8.6% [3] - The current status of estimate revisions translates into a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [6] Future Outlook - The current consensus EPS estimate for the upcoming quarter is $1.62 on revenues of $2.84 billion, and for the current fiscal year, it is $5.28 on revenues of $11.14 billion [7] - The outlook for the insurance industry, particularly the Property and Casualty sector, is currently in the top 35% of Zacks industries, suggesting a favorable environment for stock performance [8]

Core Insights - V.F. Corporation (VFC) is expected to report a year-over-year decline in both revenue and earnings for the first quarter of fiscal 2026, with revenues estimated at $1.7 billion, reflecting an 11.2% decrease from the previous year [1][9] Revenue Performance - The consensus estimate for VFC's loss is set at 34 cents per share, slightly wider than the 33 cents reported in the same quarter last year [2] - Management anticipates a revenue decline of 3-5% on a constant currency basis, primarily due to brand-specific challenges and reduced consumer traffic [3] - Vans brand performance is expected to mirror a 20% decline seen in the previous quarter, significantly impacting overall revenue [4] Operational Challenges - The fiscal first quarter is typically the smallest for VFC and is heavily influenced by Vans' performance, with ongoing strategic resets and store closures affecting results [3][4] - Foreign exchange fluctuations are also expected to negatively impact revenue, adding further pressure [5] Margin and Cost Structure - Despite revenue challenges, gross margin is projected to remain strong due to lower input costs, fewer promotions, and an improved inventory mix, which previously led to a 560 basis-point improvement in gross margin [6][9] - Operating loss is expected to be between $110 million and $125 million for the first quarter, with SG&A expenses forecasted to be flat or slightly down year-over-year due to cost-saving measures [6] Stock Valuation - VFC's stock is currently trading at a forward price-to-earnings ratio of 13.87, which is higher than the industry average of 11.49 [10] - Over the past three months, VFC's shares have increased by 8.2%, outperforming the industry growth of 1.1% [11]

Core Viewpoint - AbbVie is expected to report second-quarter 2025 earnings on July 31, with sales estimated at $15.07 billion and earnings per share (EPS) at $2.89, although earnings estimates have declined recently [1][4][5] Financial Performance - AbbVie has consistently exceeded earnings expectations in the past four quarters, with an average earnings surprise of 2.93% [2][3] - The company anticipates adjusted earnings between $2.84 and $2.88 per share for Q2 2025, with net revenues around $15.0 billion [5] Product Performance - Growth is expected to be driven by newer immunology drugs, Skyrizi and Rinvoq, with sales estimates of $4.12 billion and $1.98 billion respectively [6] - Humira, which lost patent protection in January 2023, is projected to generate $1.41 billion in sales, reflecting ongoing sales erosion [7] - Sales for Imbruvica are expected to decline due to competition, with estimates at $704 million [8] - Venclexta sales are likely to rise, estimated at $668 million, driven by strong demand [9] - Neuroscience product sales are projected at $2.47 billion, supported by strong growth in drugs like Botox and Vraylar [10][11] Market Position and Valuation - AbbVie shares have outperformed the industry this year, trading at a price/earnings ratio of 14.44, slightly below the industry average of 15.34 [13][16] - Despite challenges from Humira biosimilars, AbbVie expects robust revenue growth in 2025, with a projected high single-digit revenue CAGR through 2029 [18] Strategic Outlook - AbbVie is investing in its future pipeline through collaborations, including a recent licensing deal for an investigational antibody targeting oncology and autoimmune diseases [20] - The company’s diverse portfolio, including drugs like Venclexta, Vraylar, and others, is expected to offset losses from declining sales in certain areas [19]

Key Takeaways Vale S.A. (VALE) is expected to report a decline in its bottom and top lines when it reports second-quarter 2025 results on July 31, after market close. The Zacks Consensus Estimate for Vale's sales is pegged at $8.66 billion, indicating a 12.7% decrease from the year-ago quarter's figure. The consensus mark for earnings has moved down 25% over the past 60 days to 33 cents per share. The figure indicates a 23% year-over-year decline. | | Q1 | Q2 | F1 | F2 | | --- | --- | --- | --- | --- | | Cu ...

Core Viewpoint - Navient Corporation (NAVI) is expected to report a rise in quarterly revenues but a decline in earnings year-over-year for Q2 2025 [1][8] Revenue Expectations - The consensus estimate for revenues is $142.8 million, indicating a 5% increase compared to the previous year [2] - Consumer loan demand remained stable due to a strong labor market, which is expected to positively impact the Consumer Lending segment [3] - However, elevated prepayment due to student loan forgiveness and subdued origination volume are likely to limit revenue growth in the Federal Education Loans segment [3] Earnings Expectations - The Zacks Consensus Estimate for earnings is 29 cents per share, reflecting a 39.6% decline from the year-ago figure [2] - NAVI's earnings surprise history shows an average surprise of 27.10%, with earnings exceeding estimates in four of the last five quarters [2] Net Interest Income (NII) - The consensus estimate for Core NII is $142.9 million, indicating a sequential decline of 0.8% [4] - NII for Federal Education loans is estimated at $48.6 million, suggesting a slight rise, while consumer lending NII is expected to decline by 1.4% to $111.5 million [4] Non-Interest Income - The consensus estimate for servicing revenues is $10 million, indicating a 23.3% fall from the prior quarter [5] - Total non-interest income is estimated at $25.1 million, reflecting a 50.7% sequential decline [5] Expense Management - Cost-control measures are anticipated to enhance operating efficiency and lower expenses in Q2 2025 [6] - Strategic actions taken last year are expected to contribute to a further decline in operating expenses [6] Earnings ESP and Zacks Rank - NAVI has an Earnings ESP of -7.66%, indicating a lower likelihood of an earnings beat [7] - The company currently holds a Zacks Rank of 3 (Hold) [9]

Core Viewpoint - The market anticipates Idexx Laboratories (IDXX) will report a year-over-year increase in earnings driven by higher revenues for the quarter ended June 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - Idexx is expected to report quarterly earnings of $3.31 per share, reflecting a year-over-year increase of +35.7% [3]. - Revenues are projected to reach $1.07 billion, which is a 6.3% increase from the same quarter last year [3]. Estimate Revisions - The consensus EPS estimate has been revised 0.74% higher in the last 30 days, indicating a positive reassessment by analysts [4]. - The Most Accurate Estimate for Idexx is higher than the Zacks Consensus Estimate, resulting in an Earnings ESP of +0.34%, suggesting a bullish outlook on earnings prospects [12]. Earnings Surprise Prediction - A positive Earnings ESP is a strong indicator of an earnings beat, especially when combined with a Zacks Rank of 1 (Strong Buy), 2 (Buy), or 3 (Hold) [10]. - Idexx currently holds a Zacks Rank of 3, indicating a likelihood of beating the consensus EPS estimate [12]. Historical Performance - In the last reported quarter, Idexx was expected to post earnings of $2.92 per share but actually delivered $2.96, resulting in a surprise of +1.37% [13]. - Over the past four quarters, Idexx has exceeded consensus EPS estimates three times [14]. Conclusion - Idexx is viewed as a compelling candidate for an earnings beat, but investors should consider other factors influencing stock performance ahead of the earnings release [17].

Core Viewpoint - MVB Financial (MVBF) is expected to report flat earnings of $0.31 per share for the quarter ended June 2025, with revenues projected at $35.9 million, reflecting a 3.4% increase from the previous year [3][12]. Earnings Expectations - The consensus outlook indicates that MVB Financial's earnings will remain unchanged compared to the same quarter last year, which may influence the stock price depending on actual results versus expectations [1][3]. - A positive earnings surprise could lead to a stock price increase, while a miss may result in a decline [2]. Estimate Revisions - The consensus EPS estimate has not changed in the last 30 days, indicating stability in analyst expectations [4]. - The Most Accurate Estimate aligns with the Zacks Consensus Estimate, resulting in an Earnings ESP of 0%, suggesting no recent differing analyst views [12]. Earnings Surprise Prediction - The Zacks Earnings ESP model indicates that a positive or negative reading can predict deviations from consensus estimates, but its predictive power is stronger for positive readings [9][10]. - MVB Financial currently holds a Zacks Rank of 3, making it challenging to predict an earnings beat conclusively [12]. Historical Performance - In the last reported quarter, MVB Financial exceeded expectations by delivering earnings of $0.27 per share against an expected $0.21, resulting in a surprise of +28.57% [13]. - Over the past four quarters, the company has beaten consensus EPS estimates twice [14]. Conclusion - MVB Financial does not appear to be a strong candidate for an earnings beat based on current estimates and rankings, but investors should consider other factors before making decisions [17].

Core Viewpoint - The market anticipates CPI Card Group Inc. (PMTS) will report a year-over-year increase in earnings driven by higher revenues for the quarter ended June 2025, with actual results being crucial for stock price movement [1][2]. Earnings Expectations - The consensus estimate for quarterly earnings is $0.56 per share, reflecting a year-over-year increase of +9.8%, while revenues are expected to reach $132.25 million, up 11.3% from the previous year [3]. Estimate Revisions - The consensus EPS estimate has been revised down by 12% over the last 30 days, indicating a bearish sentiment among analysts regarding the company's earnings prospects [4][11]. Earnings Surprise Prediction - The Most Accurate Estimate for CPI Card Group is lower than the Zacks Consensus Estimate, resulting in an Earnings ESP of -6.31%, which complicates predictions of an earnings beat [11]. Historical Performance - In the last reported quarter, CPI Card Group was expected to post earnings of $0.56 per share but only achieved $0.40, resulting in a surprise of -28.57%. Over the last four quarters, the company has beaten consensus EPS estimates twice [12][13]. Overall Assessment - CPI Card Group does not appear to be a strong candidate for an earnings beat, and investors should consider other factors when making decisions regarding the stock ahead of its earnings release [16].